Clinical trials: End of Life Patients
Inherited Cardiac Arrhythmias, Long QT Syndrome
Long Term Monitoring for Risk of Sudden Death
Risk prediction in in inherited heart rhythm conditions that may cause sudden cardiac arrest or death is difficult. Sometimes the risks may be low but the loss of life in an otherwise healthy young individual is catastrophic.
- Conditions
- Inherited Cardiac Arrhythmias, Long QT Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy, Brugada Syndrome
- Trial name
- NCT04124237
- Where
- Canada
- Volunteers
- 1,051 people
- Sponsor
- University of British Columbia
Depression
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant action of ketamine in palliative care situations.
- Trial name
- KETAPAL (NCT02783430)
- Testing
- Ketamine, Milnacipran
- Where
- 9 sites in France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Lille
Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to…
- Trial name
- NCT06405230
- Testing
- Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Lichen Planus
Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
- Trial name
- NCT04892381
- Testing
- Skin Biopsy
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
Hepatocellular Carcinoma, Hepatitis C, Chronic
Primary Prevention Hepatocellular Carcinoma by Metformin
Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Chronic, Cirrhosis
- Trial name
- METFOVIR (NCT02319200)
- Testing
- Metformin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diarrhea, Death
Lactobacillus Preparation on the Incidence of Diarrhea
The purpose of this trial is to clarify the impact of lactobacillus preparation on the incidence of diarrhea in ICU-admitted patients.
- Conditions
- Diarrhea, Death, Pneumonia
- Trial name
- NCT01792739
- Testing
- Lactobacillus casei variety rhamnosus granules
- Where
- 3 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- Seoul National University Hospital
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC.
- Trial name
- NCT01846416
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
- Where
- 31 sites in United States, Belgium and 3 more
- Volunteers
- 138 people
- Sponsor
- Genentech, Inc.
Dialysis, Quality of Life
Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Patients with end-stage kidney disease are treated with dialysis to increase their life expectancy as well as their quality of life (QoL).
- Conditions
- Dialysis, Quality of Life, Nutrition
- Trial name
- NCT03910426
- Testing
- Blood sampling, Nails collection, Stool collection
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- BIRCH (NCT02031458)
- Testing
- Atezolizumab
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 667 people
- Sponsor
- Hoffmann-La Roche
Coronary Vasospasm, Cardiac Death
Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry
The purpose of this study is to evaluate the natural course of coronary spasm patients presenting aborted sudden cardiac death and analyze risk factors.
- Trial name
- NCT02298543
- Testing
- coronary spasm
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seung-Jung Park
Terminal Care
Living Well, Dying Well. a Research Programme to Support Living Until the End
The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e.
- Trial name
- iLIVE (NCT04271085)
- Testing
- Observational study
- Where
- 11 sites in Argentina, Germany and 9 more
- Volunteers
- 1,500 people
- Sponsor
- Erasmus Medical Center
Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid…
- Trial name
- NCT02541604
- Testing
- Atezolizumab
- Where
- 30 sites in United States, Canada and 9 more
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Covid19
Spanish Study to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19
The aim of this study is prospectively analyzing the histopathological, ultrastructural and microbiological findings from autopsies performed on patients with COVID-19.
- Trial name
- NCT04772833
- Testing
- Autopsy
- Where
- 10 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Solid Tumors, Lymphoma
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid…
- Trial name
- NCT03010176
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade.
- Trial name
- NCT03003676
- Testing
- ONCOS-102, Cyclophosphamide, Pembrolizumab
- Where
- 4 sites in United States, Norway
- Volunteers
- 21 people
- Sponsor
- Targovax Oy
Suspected Damage to Fetus From Other Disease in the Mother, Affecting Management of Mother, With Delivery, Patient Death or Serious Disability Associated With A Haemolytic Reaction Due to the Administration of ABO-Incompatible Blood or Blood Products
The Use of Lung Ultrasonography in the Delivery Room in Neonates
Lung ultrasonography has become frequently used in neonatal intensive care units because it is a diagnostic, useful, harmless, radiation-free, bedside, reproducible and practical method.
- Trial name
- LUSIN (NCT06314789)
- Testing
- doing lung ultrasonography
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Kırıkkale University
ESRD (End Stage Renal Disease), Dialysis
Laser Acupuncture for Fatigue in Hemodialysis Patients
The goal of this clinical trial is to learn if laser acupuncture (low-level laser therapy) works to treat fatigue and improve quality of life in adults with end-stage renal disease (ESRD) undergoing hemodialysis.
- Conditions
- ESRD (End Stage Renal Disease), Dialysis, Fatigue
- Trial name
- LA-HD-Fatigue (NCT07538310)
- Testing
- Low-Level Laser Acupuncture (LA)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei City Hospital
Tissue and Organ Harvesting, Liver Transplantation
Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death
According to the French Biomedicine Agency annual report on retrieval activities and transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012.
- Conditions
- Tissue and Organ Harvesting, Liver Transplantation, Brain Death
- Trial name
- FIBROSCAME (NCT02460250)
- Testing
- Fibroscan
- Where
- 19 sites in France
- Volunteers
- 740 people
- Sponsor
- University Hospital, Limoges
Solid Tumors and Lymphomas
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
- Trial name
- NCT03172936
- Testing
- MIW815, PDR001
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals